IAM · NASDAQ · Healthcare · $636.6M
$13.43-6.0%vs prev closeclose of 2026-10-30 · not real-time
Some axes lack data (–)
A summary of valuation factors — not a buy recommendation. You decide.
| Company | PER | PBR | ROE | Div | Score |
|---|---|---|---|---|---|
| Iambic Therapeutics Inc. | – | – | – | 0.0% | – |
| Starling Oncology Inc. | – | – | – | 0.0% | 40 |
| Ironwood Pharmaceuticals Inc. | 4.5 | – | – | 0.0% | 82 |
| Puma Biotechnology Inc | 20.5 | 3.9 | 22% | 0.0% | 59 |
| Tactile Systems Technology Inc. | 21.3 | 2.3 | 12% | 0.0% | 61 |
| NRC Health | 88.3 | – | 248% | 2.7% | 58 |
Same sector, nearest by market cap · – = no data (value traps excluded)
Open-market buys & sells by this company's officers & directors (SEC Form 4)
Observational — buy/sell facts only, not a recommendation. Filing dates (the trade was 1–2 business days earlier). Routine comp (option exercises, grants) excluded — discretionary buys/sells only.
The chart (long-term trend, Ichimoku cloud) is for observation only — not a buy or sell signal.
A highlight of the key metrics detailed below.
Top-tier in 0 of 1 evaluated strategies
Ranks within the US market — tap to open that ranking (ranks are per market).
Past returns — they do not guarantee future results.
EV as reported by our data provider (Yahoo Finance) · net debt is our own calc (total debt − cash) · definitions differ, so EV need not equal market cap + net debt (minority interest, preferred stock)
A Japanese trend tool. Price above the 'cloud' is supportive; below is weak. A strong uptrend doesn't mean it's cheap — stocks that have run up are usually more expensive.